Meibomian Gland Disease Treatment Drug Market

Key data points: Market size in 2027 = $1.7 billion and 2035 = $3.3 billion growth forecast = 8.7% annually for the next 8 years. This market report covers trends, opportunities, and forecasts in the global meibomian gland disease treatment drug market to 2035 by type (oral and topical), application (hospital pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Meibomian Gland Disease Treatment Drug Market The future of the global meibomian gland disease treatment drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global meibomian gland disease treatment drug market is expected to reach an estimated $3.3 billion by 2035 from $1.7 billion in 2027 with a CAGR of 8.7% from 2027 to 2035. The major drivers for this market are increasing prevalence of dry eye syndrome and ongoing advancements in treatment options and diagnosis techniques. • Lucintel forecasts that, within the type category, oral is expected to witness a higher growth over the forecast period due to increasing use of 3D modeling in construction design. • Within the application category, retail pharmacy is expected to witness a higher growth over the forecast period due to increased use of BIM for design visualization and coordination. • In terms of regions, North America is expected to witness the highest growth over the forecast period due to rapid construction and infrastructure development in the region. A more than 150-page report is developed to help in your business decisions. Emerging Trends in Meibomian Gland Disease Treatment Drug Market The treatment of Meibomian gland disease is shifting from management of symptoms toward restoration of the glands and stability of the tear film. During the years 2025 through 2027, prescription, therapeutic, and diagnostic launches will be followed by increased industry scrutiny by payers. Lucintel suggests that these drug launches will be successful if they are able to incorporate clinically meaningful differentiators, and formulate a stronger value proposition for the ophthalmology specialty. • Anti-inflammatory Drugs: Drug development will continue to progress beyond the use of broad-spectrum corticosteroids toward anti-inflammatory therapy targeted specifically at the meibomian glands. The goal of phase 3 therapy is to assess both the reduction of symptoms and improvement in the function of the glands. This differentiating goal from previous phases will shape prescribing patterns moving forward. • Chronic Therapy Delivery: Chronic therapy adherence remains a significant issue for a number of chronic therapy therapeutic eye care regimens. Due to significant adherence issues, companies have begun to formulate therapies designed to reduce dosing frequency and use of sustained-release and slow-release therapy matrices. • Diagnostic-led Treatment: There is growing adoption of meibography, non-invasive assessment of the Tear Film Break-Up Time, and tests of osmolarity of tears. An influential 2025 clinical review concluded that 86% of dry eye cases demonstrate some degree of meibomian gland dysfunction. This specific diagnosis will allow for focused therapeutic intervention thereby eliminating the practice of empiric therapy. • Combination Regimens: The 2026 practice discussions will look at the timing of multiple interventions rather than single modalities. Adding anti-inflammatory medications to thermal expression, intense pulsed light, and lipid-based lubricants will help increase treatment time and create a need for branded medications along the comprehensive care pathway for dry-eye therapy. • Evidence-led Market Access: Payer and ophthalmology networks will require stronger comparative evidence within the next 2-3 years when branded products will experience reimbursement pressure. Manufacturers showing products with less recurrence, better gland morphology, or lower downstream surgical rates will result in better positioning on the formulary in the next 3-5 years. It is expected that dry-eye therapy will expand, although not through volume growth. Therapies that meet the criteria of safe, effective, and economically justifiable will be selected. Diagnostic innovations will help identify the appropriate and specific therapies for individual dry-eye diseases. Superior alignment of the clinical endpoints of therapy with adherence and economic outcomes of the payers will dominate the therapy dry-eye and sustain market position throughout 2027 and beyond. Recent Developments in the Meibomian Gland Disease Treatment Drug Market The market for drugs to treat Meibomian gland disease is evolving from symptomatic to prescription based, Targeted drug development is active for 2025-2027, with several candidates for anti-inflammatory drugs tested, and evidence for regulatory submissions is being prepared, along with advances to form partnerships with Ophthalmology focused services. Lucintel projects that as these drugs are developed, a growing number of clinicians will adopt a more active approach to provide patients with alternatives to the use of artificial tears or in office procedures. • Targeted Inflammation Control: In March 2025, Azura Ophthalmics reported that it was continuing the development of its meibomian gland dysfunction drug candidate, AZR-MD-001, a topical therapy meant to control inflammation and potentially alter the course of Meibomian gland dysfunction. AZR-MD-001 has the potential to provide a prescription based therapy to address the meibomian gland dysfunction unmet medical need beyond the current short term artificial tear based therapies. • Clinical Evidence as The Key Differentiator: In June 2025, Clinical Trials.gov posted multiple interventional studies on MGD drug candidates. The new studies reflect an emphasis on the control of endpoints such as tear film stability and meibum secretion, where clinical evidence will control reimbursement and clinical adoption. • Increase Treatment Frequency with Combination Therapy: In September 2025, combination therapies with topical drugs in conjunction with thermal expression of meibomian gland secretion and lid-margin hygiene began to be actively studied by over 100 participants. • Specialty Ophthalmology Increases Spending: In February 2026, small to mid-cap ophthalmology focused companies focused their pipeline spending on MGD, and other ocular surface programs. Investment will favor advanced clinical candidates to retain a competitive edge in the marketplace. • Regulatory Focus Shifts To Chronic-use Safety: For emerging MGD therapies, anticipated late stage readouts in 2027 will weigh heavily on the six-month tolerance and sustained benefit. Products with sustained benefits will help differentiate durable prescription therapies from the short-lived symptom relief therapies, and may also determine the order therapies are listed on insurance coverage (formulary) lists. The commercial success of products will depend more holistically on the outcome of restoring gland function and reducing the need for repeated medical interventions. Tolerability and durability will help differentiate these products from one another. There is expected continued pressure on pricing, especially for therapies that are largely reimbursed as supportive care by the insurers. However, products that are able to successfully cross the regulatory hurdles and serve the therapeutic need will be able to raise subsequent rounds of investment capital. Strategic Growth Opportunities in the Meibomian Gland Disease Treatment Drug Market The Meibomian gland disease treatment market will shift from temporary symptom relief to the restoration of the glands and the development of long-term control. Between 2024 and 2026, ocular surface therapies are expected to gain increased regulatory interest. This will be coupled with increased workplace productivity-related employer costs, as well as an expansion of dry eye disease diagnosis. According to Lucintel, increased competition is anticipated as prescription drugs, generics, devices, and combinations will target defined outcomes. • Restoration Therapies: Therapies that restore meibomian glands have the potential for higher market value than currently available lubricants. In January 2025, TFOS DEWS III identified meibomian gland dysfunction as a primary mechanism of dry eye disease. In the next five years, the focus of treatment is expected to become modification of the disease process, and consequently, the prescription of repeated treatment courses will become the standard of care. • Anti-inflammatory Combos: Restoration therapies coupled with anti-inflammatory treatments offer the potential to improve treatment adherence through the use of fixed or flexible dose combination therapies. In March 2025, the American Academy of Ophthalmology reported that dry eye disease affects over 16 million diagnosed U.S. adult patients. Combination therapies have the potential to target those patients who do not respond to a single course of therapy. • Presbyopia Care and Screen-related Distress: The combination of digital device use and aging further expands this significant market segment as the symptoms of dry eyed conjunctivitis occur in cases of visual stress. In February 2025, a report released by the U.S. National Eye Institute stated that dry eye disease is caused or exacerbated by the use of computers and other digital devices. Dry-eye related symptoms will also expand the capacity of retail clinics and optometry networks. • Emerging Market Expansion: Pricing customization, physician education, and pharmacy distribution can offer access to treatment beyond North America and Western Europe. Estimated at about 3% of GDP, India’s healthcare spending was expected to grow in 2025. Increasing urban screen usage and growing ophthalmology capacity create opportunities for regional brands and licensing partnerships. • Personalized Monitoring Services: Tear-film testing along with imaging of the glands and digital reporting of symptoms can correlate drug selection with a measurable response. TFOS recommendations, released in May 2025, continued to stress the need for objective assessment in addition to the symptoms of the patient. Within the next 3 to 5 years, monitoring will be justified to achieve premium reimbursement, purposeful switching, and the adoption of a subscription model for follow-up. Those who will win the market will not make just one eye drop. They will create a product that provides long-lasting symptom management that clinicians can measure and patients can perceive. The best opportunities will be in the area at the intersection of diagnostics, adherence, and access, as well as in the area of the differentiation of the function of the lacrimal gland and age of the patient, taking into account the care environment. Meibomian Gland Disease Treatment Drug Market Drivers and Challenges Growth in awareness of meibomian gland disease, coupled with aging, more sophisticated diagnostics, and greater innovation and investment in pharmaceuticals, drives market growth in treatments for meibomian gland disease. Clinical adoption, pricing, reimbursement, and competition are impacted by a combination of technology, economics, and regulations. The demand is for longer-acting therapies that are preservative-free and targeted. Lucintel has found that although clinical evidence, costs, and uncertain regulations remain, there are many opportunities for market expansion across major regions due to limited clinical evidence and significant costs. The factors responsible for driving this market include: • Customer Demand: More people use digital devices, Older population; more contact lens wear and greater awareness of evaporative dry eye (allied with greater awareness of meibomian gland disease) leads to greater demand for both prescription and over-the-counter treatments. In 2025, 5 billion people were estimated to be using digital devices, which aids in the greater recognition of symptoms of the eye surface. In the next 3-5 years, patients will become more demanding for treatments that provide longer relief and greater convenience. This will encourage clinicians to increasingly adopt combination drug therapies. • Technology: Improved diagnosis is facilitated through improvements in tests focused on the lipid layer, meibography, artificial intelligence enhanced imaging and AI specific drug delivery. In 2025, faster assessment of images for automated gland loss was beginning to occur due to the increasing use of AI and datasets containing thousands of ophthalmic images. In the next 3-5 years, reductions in the misclassification of meibomian gland disease patients will occur, leading to personalized therapy, a greater ability to provide appropriate treatment based on the underlying pathology, and greater evidence for drug treatment of chronic Meibomian gland associated inflammation and obstruction, as well as dysfunction of the tear film. • Product Innovation: New products in pharmaceutical development target multiple pathophysiology's of meibomian gland dysfunction. For the next 3-5 years, new drug mechanisms, combination therapies, and less complex dosing schedules will likely extend the current market for products beyond artificial tears and office procedures. Preservative-free drug delivery systems and formulations also continued development in 2025. This will likely continue to drive medication adherence. • Regulatory Support: Reduced uncertainty in the regulatory climate is possible with more defined pathways for ophthalmic drugs, “orphan” or expedited development, and increased clinical interest in dry eye disease. In 2025, regulators demanded more complete controlled clinical evidence for the safety and quality of ophthalmic products. For the next 3-5 years, the standardization of agreed-upon endpoints for gland function and tear film stability and patient-reported outcomes will improve the chances for approval of new, differentiated therapies. • Manufacturing Efficiency: Lost production can be reduced by improvements in preservative-free packaging, regional sourcing, and stable formulations through enhanced management of commercial losses. In 2025, preservative-free ophthalmic packaging continued to be an area of focus in manufacturing. For the next 3-5 years, improved packaging will reduce cost, extend distribution, and bring advanced therapies to cost-constrained healthcare systems. The challenges facing this market include: • Variation of Clinical Evidence: There are no universally accepted thresholds to define Meibomian gland disease and clinical studies use diverse symptom scales and imaging techniques with varied endpoints of treatment. In 2025, many ophthalmic studies continued to use follow-up studies or observation periods that were approximately 12 weeks. During this period of time, it may be challenging to assess the long-term changes that may occur to the glands. It is anticipated that during the next 3 to 5 years, there will be several different views and a notable lack of evidence that will delay regulatory decisions and slow the approval of similar products. Additionally, it would likely be discouraged for physicians to consider switching to alternative products. • High Treatment Cost: The combination of prescribed therapies, consultations, repeated diagnostic studies, and the cost of treatment can place a significant financial burden on the patient and the health care system. In 2025, the specialty medical therapies in various markets continued to have limited reimbursement and significant out of pocket costs. It is anticipated that over the next 3 to 5 years, financial considerations will limit the adoption of therapies for conditions that are perceived as non-life threatening and increased evidence that combines the financial impact of health care therapies and the impact on the health care system will be required for reimbursement. • Diagnosis and Adherence Barriers: A combination of the symptoms of Meibomian gland disease and aqueous deficient dry eye disease, allergy, blepharitis, and contact lens irritation contribute to underdiagnosis and inappropriate treatment. In 2025, patients often were managed with extensive regimens consisting of frequent drops and meals combined with daily heat therapy, hygiene, and frequent follow-up visits. It is anticipated that in the next 3 to 5 years, the complexity of diagnosis and the burden of treatment will contribute to reducing the effectiveness and adherence to treatment and will require the integration of ophthalmology care and more straightforward, less frequent dosing combined with targeted patient education. The treatment market for meibomian gland disease is expected to grow due to the combination of patient demand, new technologies for diagnosis, and improvements in pharmaceuticals. Growth can be enhanced by the improvements in manufacturing and regulatory processes. Even with these advancements, clinical definitions for the disease are difficult to define, it’s expensive, reimbursements are difficult to get, and patients are unable to adhere to current treatments. Adoption for new treatments will depend upon demonstrating improvements with effective therapies that are safer and of greater benefit to patients. List of Meibomian Gland Disease Treatment Drug Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies meibomian gland disease treatment drug market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the meibomian gland disease treatment drug market companies profiled in this report include- • Pfizer • AbbVie • Johnson and Johnson Service • Bausch Health Companies • Novartis • RegeneRx • Akorn Meibomian Gland Disease Treatment Drug Market by Segment The study includes a forecast for the global meibomian gland disease treatment drug by type, application, and region. Meibomian Gland Disease Treatment Drug Market by Type [Value ($B) from 2019 to 2035]: • Oral • Topical Meibomian Gland Disease Treatment Drug Market by Application [Value ($B) from 2019 to 2035]: • Hospital Pharmacies • Retail Pharmacies • Others Meibomian Gland Disease Treatment Drug Market by Region [Value ($B) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Meibomian Gland Disease Treatment Drug Market As the market for treatments for Meibomian Gland Disease (MGD) shifts from supportive care to prescription therapies, evidence for tear-film and gland dysfunction from 2025 to 2027 will be the main driver for market entry, adoption, and evidence following regulatory approval. Based on the latest market data from Lucintel, country level execution will still be the most important factor. • United States: Prescription therapies: Following FDA approval of perfluorohexyloctane (MIEBO) in May 2023 and continued commercial efforts by Bausch + Lomb in 2025 for the product and targeting a broader indication of dry eye, the establishment of the first prescription therapy targeting gland dysfunction is influencing the clinical pathway, payer discussions, and the development of other therapies in the dry eye space for the next 3-5 years. • China: Local innovation: In 2025, the Chinese National Medical Products Administration approved 0.01% cyclosporine ophthalmic solution, Vevizye, as an immunomodulatory therapy for prescription dry eye. This is important because local approval would likely accelerate the inclusion of therapies on hospital formularies and encourage the development and market entry of Chinese companies for therapies targeting the dysfunctions of evaporative and inflammatory diseases. • Germany: European access: Following the European Commission’s decision in July 2025 for the marketing authorization of perfluorohexyloctane, Germany enabled the prescription of the therapy across the European Union. The authorization is of significance for Germany’s reimbursement assessments and prescribing by specialists and is expected to impact the investment for ocular surface therapies. • India: Market openness and production: In 2025, the Central Drugs Standard Control Organization in India continued implementing steps to augment oversight for ophthalmic products. Local manufacturers continued developing and building offerings for dry eye syndrome. This new development is important because the scale, pricing, and procurement sensitivity of India’s growing ophthalmology market can provide advances in new MGD therapies beyond private practice in metropolitan areas. • Japan: Regulatory localization: The Pharmaceuticals and Medical Devices Agency of Japan continued reviewing ophthalmic medicines in 2025, while bridging and post marketing studies for dry eye syndrome drugs continued. This is important because the Japanese market’s aging population and the requirement of specialized prescribing and unique reimbursement creates a need for local evidence for sustained adoption of MGD drugs. Features of the Global Meibomian Gland Disease Treatment Drug Market Market Size Estimates: meibomian gland disease treatment drug market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: meibomian gland disease treatment drug market size by type, application, and region in terms of value ($B). Regional Analysis: meibomian gland disease treatment drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the meibomian gland disease treatment drug market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the meibomian gland disease treatment drug market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the meibomian gland disease treatment drug market by type (oral and topical), application (hospital pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?